ArticleCureus2025
Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Euglycaemic ketoacidosis associated with dual-acting GLP-1/GIP receptor agonist treatment following bariatric surgery.Endocrinology, diabetes & metabolism case reports · 2026Article
- Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.Proceedings (Baylor University. Medical Center)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dulaglutide is a glucagon-like peptide (GLP-1) receptor agonist approved by the Food and Drug Administration in patients with type 2 diabetes mellitus (T2DM) with noted cardiovascular and renal benefits along with weight loss. Dulaglutide's most common adverse effects include fatigue, poor appetite, abdominal pain, nausea, vomiting, and diarrhea. Although typically associated with the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, there have been case reports of GLP-1 receptor agonists leading to euglycemic diabetic ketoacidosis (DKA). We present a case of dulaglutide use leading to euglycemic DKA, a rare but life-threatening adverse effect after re-initiation of the medication at a higher dose. Our patient presented with non-specific gastrointestinal symptoms and weakness, which both resolved after the initiation of an insulin drip and intravenous fluids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.